Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy.
暂无分享,去创建一个
Matthias Reimold | Gerald Reischl | Roland Bares | Helmut Dittmann | H. Dittmann | S. Welz | M. Reimold | G. Reischl | H. Machulla | R. Bares | F. Paulsen | S. Eschmann | Susanne-Martina Eschmann | Frank Paulsen | Stefan Welz | Hans-Juergen Machulla
[1] T. Nishimura,et al. Kinetics of a putative hypoxic tracer, 99mTc-HL91, in normoxic, hypoxic, ischemic, and stunned myocardium. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[2] M J Welch,et al. Radiolabeled hypoxic cell sensitizers: tracers for assessment of ischemia. , 1987, Life sciences.
[3] T K Lewellen,et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. , 1996, International journal of radiation oncology, biology, physics.
[4] K L Lindsley,et al. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. , 1995, International journal of radiation oncology, biology, physics.
[5] J. Rasey,et al. Characteristics of the binding of labeled fluoromisonidazole in cells in vitro. , 1990, Radiation research.
[6] C C Ling,et al. Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. , 2000, International journal of radiation oncology, biology, physics.
[7] M. Piert,et al. Introducing fluorine-18 fluoromisonidazole positron emission tomography for the localisation and quantification of pig liver hypoxia , 1999, European Journal of Nuclear Medicine.
[8] I. Olivotto,et al. Gel electrophoresis of individual cells to quantify hypoxic fraction in human breast cancers. , 1993, Cancer research.
[9] J. Eary,et al. [18F]FMISO and [18F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[10] Chapman Jd,et al. Hypoxic sensitizers--implications for radiation therapy. , 1979 .
[11] P Vaupel,et al. Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. , 1993, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[12] B. Movsas,et al. Marking Hypoxia in Rat Prostate Carcinomas with β-d-[125I]Azomycin Galactopyranoside and [99mTc]HL-91: Correlation with Microelectrode Measurements , 2001 .
[13] J. Verdebout,et al. The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis , 2002, British Journal of Cancer.
[14] V. Oikonen,et al. Imaging of blood flow and hypoxia in head and neck cancer: initial evaluation with [(15)O]H(2)O and [(18)F]fluoroerythronitroimidazole PET. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[15] M. Piert,et al. Dependency of the [18F]fluoromisonidazole uptake on oxygen delivery and tissue oxygenation in the porcine liver. , 2000, Nuclear medicine and biology.
[16] K. Krohn,et al. Radiolabelled fluoromisonidazole as an imaging agent for tumor hypoxia. , 1989, International journal of radiation oncology, biology, physics.
[17] P. Olive,et al. Hypoxic fractions measured in murine tumors and normal tissues using the comet assay. , 1994, International journal of radiation oncology, biology, physics.
[18] M. Graham,et al. A modeling approach for quantifying tumor hypoxia with [F-18]fluoromisonidazole PET time-activity data. , 1995, Medical physics.
[19] M. Dewhirst,et al. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. , 1997, International journal of radiation oncology, biology, physics.
[20] Marianne Patt,et al. [18F]Fluoroazomycinarabinofuranoside (18FAZA) and [18F]Fluoromisonidazole (18FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors. , 2003, Nuclear medicine and biology.
[21] K. Krohn,et al. Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells. , 1987, Radiation research.
[22] M. Dewhirst,et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. , 1996, Cancer research.
[23] C. Koch,et al. 2-Nitroimidazole (EF5) binding predicts radiation resistance in individual 9L s.c. tumors. , 1996, Cancer research.
[24] David J. Yang,et al. Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia. , 1995, Radiology.
[25] H. Machulla,et al. Preparation of [18F]fluoromisonidazole by nucleophilic substitution on THP-protected precursor: Yield dependence on reaction parameters , 1999 .
[26] Michael J. Welch,et al. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM , 2003, European Journal of Nuclear Medicine and Molecular Imaging.